CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Event

Investors

OMX Stockholm

( %)
HNSA  SEK

The share

Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.

Antibodies
Latest Financial Results

Interim report January-September 2025

Press release Report Presentation Webcast
View all results
Calendar

Upcoming events

13
Nov

SEB Healthcare Conference, Stockholm

18
Nov

Jefferies Global Healthcare Conference in London

25
Nov

DNB Nordic Healthcare Conference 2025 Oslo

View all events

Press releases

Our latest press releases

Read all news

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results

Regulatory press release

30/10/2025
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

29/10/2025
Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

10/10/2025
Hansa Biopharma to host Q3 2025 interim results conference call

08/10/2025

Hansa Biopharma in brief

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.

Page: /

Hansa Biopharma Corporate Presentation September 2025

View presentation

Annual Report 2024
Sustainability Report 2024

Science-led
Patient first
Values driven

Read the reports

Upcoming Key Catalysts

Desensitization: Transplantation and Gene Therapy

Kidney Transplant: BLA filing with the FDA, requesting priority review

Phase 2 Top Line Data Readout: global trial in Crigler Najjar with Genethon (GNT-018-IDES)

Autoimmune Disease

Phase 3 Top Line Data Readout: global trial in anti-GBM (GOOD-IDES-02)

Phase 2 Data Publication: single arm trial in GBS (15-HMedIdeS-09)

Focus areas Pipeline
Investor relations

Evan Ballantyne

Chief Financial Officer

Email: [email protected]

E-mail

Sign up to receive the latest updates

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.